Adial Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $13.6M
- Price
- $6.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.34%
- Volume
- 82.0K
About
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Quick stats
Shares outstanding2.2M
Computed float2.1M
Float / shares96.6%
Cash runway (months)4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001513525
Websitehttps://www.adialpharma.com
AI Summary
AI-generated1/9
majorbullishearnings
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported its Q2 2026 financial results, highlighting the completed acquisition of Azora Therapeutics which adds AT177, a colon-targeted treatment for ulcerative colitis, to its pipeline.
The company strengthened its balance sheet by closing the initial $32 million tranche of a $64 million private placement, increasing cash to $28.7 million and extending its runway into the second half of 2027.
Net loss for the quarter was $52.0 million, or $11.25 per share, driven primarily by a non-cash $46.2 million charge related to the acquired in-process research and development from the Azora transaction.
Red flags
- Stockholders’ Deficit of $38.4 million as of June 30, 2026
- Net loss per share increased significantly driven by acquisition-related charges
- Stockholders' Deficit includes mezzanine equity classification pending stockholder approval